Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Clearside Biomedical, Inc. - Common Stock (NQ:CLSD)

0.8810 -0.0188 (-2.09%)
Streaming Delayed Price Updated: 2:51 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clearside Biomedical, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Clearside Biomedical And 3 Other Stocks Under $3 Insiders Are Buying
The Dow Jones closed higher by over 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
What 8 Analyst Ratings Have To Say About Clearside Biomedical
Via Benzinga
Clearside Biomedical: Q1 Earnings Insights
Via Benzinga
What 6 Analyst Ratings Have To Say About Clearside Biomedical
Via Benzinga
Where Clearside Biomedical Stands With Analysts
Via Benzinga
What 5 Analyst Ratings Have To Say About Clearside Biomedical
Via Benzinga
A Preview Of Clearside Biomedical's Earnings
Via Benzinga
Analyst Expectations for Clearside Biomedical's Future
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2023
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Analyst Bumps Up Clearside Biomedical Target Price After Encouraging Trial Data
Via Benzinga
Clearside Biomedical: Q1 Earnings Insights
Clearside Biomedical (NASDAQ:CLSD) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
United Airlines To Rally Around 54%? Here Are 10 Other Analyst Forecasts For Friday
Piper Sandler raised the price target for Riskified Ltd. (NYSE: RSKD) from $6 to $8. Piper Sandler analyst Brent Bracelin upgraded the stock from Neutral to Overweight. Riskified shares rose 2.4% to... 
Via Benzinga
Clearside Biomedical Touts Encouraging Durable Data From Investigational Candidate For Vision Disorder
Clearside Biomedical Inc (NASDAQ: CLSD) announced results from the Extension Study of its OASIS Phase 1/2a trial of CLS-AX (axitinib) administered by suprachoroidal injection via SCS Microinjector in... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
AiViva Reports That Their Promising New Treatment For Wet AMD Is Soon To Be Ready For Clinical Trials
Visit https://www.startengine.com/aiviva to invest in AiViva’s StartEngine Campaign. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2022
Upgrades 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Monopar Therapeutics (NASDAQ:MNPR) shares increased by 53.0% to $4.09 during Wednesday's pre-market session. The company's market cap stands at $52.0 million. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Clearside Biomedical (NASDAQ:CLSD) stock rose 27.3% to $1.35 during Thursday's pre-market session. The market value of their outstanding shares is at $81.2 million. 
Via Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap: Clearside Biomedical Q2 Earnings
  Clearside Biomedical (NASDAQ:CLSD) reported its Q2 earnings results on Tuesday, August 9, 2022. Here's what investors need to know about the announcement. Earnings Clearside Biomedical reported... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
  
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End of The Day Summary
Via Benzinga
Clearside Biomedical Sees Initial-Stage Chronic Eye Disorder Study Results In Q4 2022
Clearside Biomedical (NASDAQ: CLSD) has completed dosing in Cohorts 3 and 4 of OASIS study of its lead drug CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.